Helix BioPharma Corp announced the appointment of Artur Gabor as the company's new permanent CEO, effective immediately.
The clinical-stage biopharmaceutical company also said it has added Jerzy Leszczyński, Christopher Maciejewski, and Jacek Antas as new members to its board of directors.
“It's a pleasure to welcome these three distinguished members to join the Board of Helix. I look forward to working closely with them on Helix's next growth chapter,” Gabor said in a statement.
READ: Helix BioPharma announces sudden passing of interim CEO Slawomir Majewski
Helix BioPharma noted the board appointments are designed to improve the company's independence, diversification and corporate governance with an aim of strengthening its future growth capabilities.
Leszczyński, a Helix BioPharma shareholder, has served in the capacity of board member of various real estate development companies, while Maciejewski is a consultant to an international flight medicine transport service and Antas has spent more than 25 years in the financial services industry holding various positions in sales and consulting, the company said.
Helix BioPharma is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer-based on its proprietary technological platform DOS47.
Contact Sean at sean@proactiveinvestors.com